Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor‐mobilized patients with sickle cell disease. (23rd June 2022)

• Record Type: Journal Article
• Authors: Sharma, Akshay; Leonard, Alexis; West, Kamille; Gossett, Jeffrey M.; Uchida, Naoya; Panch, Sandhya; Stroncek, David; Poston, Leigh; Akel, Salem; Hankins, Jane S.; Fitzhugh, Courtney; Hsieh, Matthew M.; Kang, Guolian; Tisdale, John F.; Weiss, Mitchell J.; Zheng, Yan
• Is Part Of: British journal of haematology. Volume 198:Number 4(2022)
• Page Start: 740
• Page End: 744
• Publication Date: 2022-06-23
• Subjects: transfusion medicine -- sickle cell disease -- leukapheresis; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18311
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We adjusted haematopoietic stem and progenitor cell (HSPC) apheresis collection from patients with sickle cell disease (SCD) by targeting deep buffy coat collection using medium or low collection preference (CP), and by increasing anticoagulant–citrate–dextrose–solution A dosage. In 43 HSPC collections from plerixafor‐mobilized adult patients with SCD, we increased the collection efficiency to 35.79% using medium CP and 82.23% using low CP. Deep buffy coat collection increased red blood cell contamination of the HSPC product, the product haematocrit was 4.7% with medium CP and 6.4% with low CP. These adjustments were well‐tolerated and allowed efficient HSPC collection from SCD patients.